News
Most Clinicians Do Not Order MRI/CT for Nonspecific Low Back Pain
Low back pain (LBP) is a highly prevalent public health problem. Not surprisingly, imaging of LBP is also an expensive and often overused diagnostic tool.
ACP Guidelines on the Diagnosis and Treatment of Low Back Pain
Low back pain (LBP) is the fifth most common reason for all physician visits in the United States and nearly 25% of all U.S. adults have had LBP in the last 3 months and nearly 6% reported at least 1 episode of severe acute low back pain in the last 1-year.
Early Intervention with Corticosteroids and IVIG is Crucial in Kawasaki Disease
The current JAMA Pediatrics issue has published a report showing that adjunctive corticosteroid therapy yielded significantly fewer coronary artery complications compared with intravenous immunoglobulin therapy alone, particularly among high-risk patients with Kawasaki disease.
RheumNow Week in Review – 21 October 2016
Dr. Cush Reviews Highlights from the past week on RheumNow.com. Register to receive free daily rheumatology news written by rheumatologists for rheumatologists. Download the podcast at iTunes.com.
Higher Lupus Disease Activity in First Year Postpartum
Most women with systemic lupus erythematosus (SLE) have no or little disease activity during pregnancy, but experience greater disease activity or overt flares during the first year postpartum, a Norwegian study has found.
Good News for Lupus Pregnancies
The Washington Post recently interviewed Dr. Eliza Chakavarty of the OMRF about the evolution in attitudes and outcomes of lupus women who wish to get pregnant.
Nor-Switch Study Shows it's Safe to Switch to a Biosimilar
The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).
Review of Herpes Zoster with Immunosuppression and Autoimmune Disease
Researchers from the University of British Columbia reported on their systematic review and meta-analysis of risk of herpes zoster (HZ) in patients receiving biologics, DMARDs and/or corticosteroids for autoimmune diseases.
Inflectra Biosimilar Ships in Late November 2016
Pfizer has announced it will ship its new FDA-approved biosimilar, Inflectra, in late November and that it will be priced at a15 percent discount to current wholesale prices.
Low-Molecular Weight Heparin Does Not Reduce Pregnancy Complications
A Lancet meta-analysis has reviewed the preventative effects of low-molecular-weight heparin (LMWH) on placenta-mediated pregnancy complications include pre-eclampsia, late pregnancy loss, placental abruption, and birth of a small-for-gestational-age (SGA) neonate.
RheumNow Week in Review – 14 October 2015
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
